Dual Antiplatelet Therapy: How Long Is Long Enough?

Area of Science:

• Cardiology
• Interventional Cardiology
• Pharmacology

Background:

• The optimal duration of dual antiplatelet therapy (DAPT) is debated due to decreasing stent thrombosis risk and increasing recognition of bleeding complications.
• Newer generation stents have improved safety profiles, prompting reevaluation of standard DAPT durations.

Purpose of the Study:

• To review landmark studies on short-duration (≤6 months) and extended-duration (>12 months) DAPT.
• To discuss prediction tools for guiding individualized DAPT duration decisions.

Main Methods:

• Review of pivotal clinical trials comparing different DAPT durations.
• Analysis of data on ischemic event rates and bleeding complications.
• Evaluation of risk prediction scores (e.g., PRECISE DAPT, DAPT score).

Main Results:

• Short-duration DAPT is safe when necessary, but may be associated with a trend towards increased ischemic events.
• Extended-duration DAPT reduces ischemic events but increases bleeding risk.
• Individualized risk assessment is crucial; short DAPT for high bleeding risk, extended DAPT for high ischemic risk.

Conclusions:

• DAPT duration should be tailored to patient-specific ischemic and bleeding risk profiles.
• Risk prediction tools can aid in selecting the appropriate DAPT duration.
• Balancing ischemic protection and bleeding avoidance is key in DAPT management.